Skip to content
Builders in Fintech

Primo Capital launches €40M Primo Biotech Lazio fund with first close

Primo Capital launches Primo Biotech Lazio, a €40M-target biotech venture fund, with a first close anchored by Lazio Innova and Fondazione ENPAM.

By Michele Mattei

Primo Capital launches Primo Biotech Lazio, a €40M-target biotech venture fund, with a first close anchored by Lazio Innova and Fondazione ENPAM.

Primo Capital has launched Primo Biotech Lazio, a venture capital fund for biotech with a €40 million target. The first close is complete, with Lazio Innova as cornerstone investor through the LAZIO Venture 2 fund of funds, which committed €17.5 million, and Fondazione ENPAM.

Letizia Goretti and Michele Cerqua are general partners, with Prof. Sergio Abrignani as scientific advisor. The fund will build a concentrated portfolio, mostly as lead investor, in biotech, advanced therapies and adjacent areas such as smart biomaterials and advanced biomedical devices. Oncology, rare diseases, neurology, immunology and regenerative medicine are among the focus areas, with a maximum of €12 million per company.

Led by CEO Antonio Concolino, Primo Capital manages more than €500 million across digital, health, climate and space funds, and is strengthening its presence in Rome with a permanent base.

ShareXLinkedIn

Have fintech news? Submit it

Get fintech news by email

Read by 25,000+ fintech builders across LinkedIn, Substack and the media platform

Which emails?

By subscribing you agree to the privacy notice. We'll email you once to confirm.

See a recent editionAll newsletters